Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: A single institution's experience

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2364-2372

  Lusby, Kristelle ^a   Savannah, Kari Brewer ^a,b   Demicco, Elizabeth G ^c   Zhang, Yiqun ^d   Ghadimi, Markus Ph ^e   Young, Eric D ^a   Colombo, Chiara ^a   Lam, Ryan ^a   Dogan, Tugce E ^a   Hornick, Jason L ^f   Lazar, Alexander J ^a,b   Hunt, Kelly K ^a   Anderson, Matthew L ^d   Creighton, Chad J ^d   Lev, Dina ^a,b   Pollock, Raphael E ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FORMALDEHYDE; GEMCITABINE; IFOSFAMIDE; KI 67 ANTIGEN; PARAFFIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTAGLANDIN RECEPTOR; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; VASCULOTROPIN;

ABDOMINAL TUMOR; ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; MULTIMODALITY CANCER THERAPY; PERITONEUM TUMOR; POSTOPERATIVE CARE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SUBCUTANEOUS TISSUE TUMOR; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; LEIOMYOSARCOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84878856089     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2834-0     Document Type: Article

References (33)

1. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer. 1997;33:907-11. (Pubitemid 27287045)
2. Giarratano RC, Slate TA. Sarcomas of the uterus. Obstet Gynecol. 1971;38:472-7.
3. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460-9. (Pubitemid 36687793)
4. Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92:648-52. (Pubitemid 38183158)
5. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999;74:196-201. (Pubitemid 29377212)
6. Loizzi V, Cormio G, Nestola D, Falagario M, Surgo A, Camporeale A, et al. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma. Oncology. 2011;81:91-7.
7. Wang WL, Soslow R, Hensley M, Asad H, Zannoni GF, de Nictolis M, et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol. 2011;35:522-9.
8. Leitao MM Jr, Zivanovic O, Chi DS, Hensley ML, O'Cearbhaill R, Soslow RA, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125:409-13.
9. Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr Opin Oncol. 2010;22:356-61.
10. Hayashi T, Shimamura Y, Saegusa T, Horiuchi A, Kobayashi Y, Hiraoka N, et al. Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression. Gene Regul Syst Bio. 2008;2:297-305.
11. Merimsky O, Gorzalczany Y, Saqi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinibmesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol. 2007;31:225-32.
12. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820-30. (Pubitemid 351240576)
13. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 1995;34:797-802.
14. Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25:783-95.
15. Demicco EG, Maki RG, Lev DC, Lazar AJ. New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol. 2012;19:170-80.
16. Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, et al. Dual targeting of mTOR and Aurora-A kinase for the treatment of uterine leiomyosarcoma. Clin Cancer Res. 2012;18:4633-45.
17. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518-27.
18. Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O'Meara AT, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol. 2003;90:402-6. (Pubitemid 36952035)
19. Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor: c-Met-driven models of leiomyosarcoma. Mol Cancer Ther. 2009;8:2803-10.
20. Bell RS, O'Sullivan B, Liu FF, Powell J, Langer F, Fornasier VL, et al. The surgical margin in soft-tissue sarcoma. J Bone Joint Surg Am. 1989;71:370-5. (Pubitemid 19116689)
21. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424-34. (Pubitemid 34183894)
22. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma: A Gynecologic Oncology Group study. Cancer. 1993;71:1702-9. (Pubitemid 23056094)
23. Burt BM, Ocejo S, Mery CM, Dasilva M, Bueno R, Sugarbaker DJ, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011;92:1202-7.
24. Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049-54.
25. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999;85:389-95. (Pubitemid 29051294)
26. Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012;125:136-40.
27. Schlüter C, Duchrow M, Wohlenberg C, Kubbutat MH, Wohlenberg C, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993;123:513-22. (Pubitemid 23324910)
28. Romagosa C, Simonetti S, López-Vicente L, Mazo A, Lleonart ME, Castellvi J, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011;30:2087-97.
29. Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG. Expression of E-cadherin, beta-catenin and topoisomerase II alpha in leiomyosarcomas. Clin Transl Oncol. 2009;11:548-51.
30. Kildal W, Pradhan M, Abeler VM, Kristensen GB, Danielsen HE. Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters. Eur J Cancer. 2009;45:2412-7.
31. Zhai YL, Kobayashi Y, Mori A, Orii A, Nikaido T, Konishi I, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18:20-8. (Pubitemid 29028841)
32. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer. 1998;22:181-90. (Pubitemid 29067392)
33. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55-64. (Pubitemid 36897935)